IDH1 and acute myeloid leukemia: Early studies established a firm association between IDH mutations and serum 2-HG concentration in AML, and confirmed that serum oncometabolite measurements provide useful diagnostic and prognostic information that can improve patient selection for IDH-targeted therapies [37].